within Pharmacolibrary.Drugs.ATC.N;

model N01AX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 11.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.00082,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Alfaxalone is a neuroactive steroid used as an intravenous anesthetic and sedative, primarily in veterinary medicine for induction and maintenance of anesthesia in dogs and cats. It enhances inhibitory neurotransmission mediated by GABA-A receptors. Not approved for human use; it is used due to its rapid onset, short duration, and favorable safety profile in animals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult female cats after single intravenous bolus of alfaxalone at a dose of 5 mg/kg.</p><h4>References</h4><ol><li><p>Dehuisser, V, et al., &amp; Polis, I (2019). Alfaxalone total intravenous anaesthesia in dogs: pharmacokinetics, cardiovascular data and recovery characteristics. <i>Veterinary anaesthesia and analgesia</i> 46(5) 605–612. DOI:<a href=&quot;https://doi.org/10.1016/j.vaa.2019.04.014&quot;>10.1016/j.vaa.2019.04.014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31395484/&quot;>https://pubmed.ncbi.nlm.nih.gov/31395484</a></p></li><li><p>Wakuno, A, et al., &amp; Ohta, M (2019). Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. <i>The Veterinary record</i> 184(13) 411–None. DOI:<a href=&quot;https://doi.org/10.1136/vr.105070&quot;>10.1136/vr.105070</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30926700/&quot;>https://pubmed.ncbi.nlm.nih.gov/30926700</a></p></li><li><p>Rodrigo-Mocholí, D, et al., &amp; Marín, P (2018). Pharmacokinetics and effects of alfaxalone after intravenous and intramuscular administration to cats. <i>New Zealand veterinary journal</i> 66(4) 172–177. DOI:<a href=&quot;https://doi.org/10.1080/00480169.2018.1455541&quot;>10.1080/00480169.2018.1455541</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29562829/&quot;>https://pubmed.ncbi.nlm.nih.gov/29562829</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N01AX05;
